Chameleon Biosciences, Inc. – Superior gene delivery technology • Minimal immune response • Repeat dosing

• SUPERIOR GENE DELIVERY TECHNOLOGY
• MINIMAL IMMUNE RESPONSE
• REPEAT DOSING

Saving children's lives,
one genetic disease at a time.

Our mission

Research indicates that 20-30% of all infant fatalities are due to genetic disorders, and for those who survive, treatment options are often limited. Recent breakthroughs in gene therapy are saving lives, but there's still a long way to go. At Chameleon, our goal is to ensure every child can be treated with lower doses and accurate target specificity over time as their condition requires.

We are committed to every child and family who suffers from a genetic disorder. Our mission is to make sure every Belle, Abby and Marian live to their 10th birthdays, learn to drive, go to prom and someday have healthy children of their very own.

BELLE

Niemman-Pick Type C Disease (Childhood Alzheimer's)
Belle was diagnosed on March 10, 2016. Her family quickly rallied and found a promising clinical trial for the disease. The drug VTS-270 is not a cure but treats the symptoms, which include gradually losing the ability to think, hear, walk, talk and eat on her own.

ABBY

Niemman-Pick Type C Disease (Childhood Alzheimer's)
Belle's younger sister, Abby, was also diagnosed just a few short weeks after Belle's diagnosis. Abby did not qualify for the clinical trial, however she was granted compassionate use of the drug. So far, she hasn't shown any symptoms.

MARIAN

Niemman-Pick Type C Disease (Childhood Alzheimer's)
Marian has been on VTS-270 for half of her life. She takes ballet, goes to preschool, adores her sister, and loves swimming, laughing with her friends and learning. For Marian and others with NPC, developing more genetic therapies means they can have a future. It means life.